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Abstract
Background: This study characterised the effects of persistent peripheral inflammation of the foot on pain and
spinal cord expression of cyclooxygenase-1 and -2 (COX-1 and COX-2) and early growth response gene 1 (Egr-1),
known markers of neuronal plasticity, in a clinical model of naturally-occurring inflammatory disease and
hyperalgesia in sheep (’footrot’), before and after routine treatment (parenteral treatment with antibiotics and
antiseptic footbathing). The temporal pattern of expression of COX-1, COX-2 and Egr-1 mRNA and protein were
analysed using real-time PCR and Western blotting.
Results: Animals affected with persistent peripheral inflammation displayed significant hyperalgesia and lameness
(a proxy indicator of spontaneous pain) restricted to the inflamed limb. Hyperalgesia and lameness were
significantly attenuated 1 day after treatment, and resolved further by day 7 and day 3, respectively. COX-2 but not
COX-1, protein expression was up-regulated in spinal cord from lame animals on day 0, before treatment.
Following treatment and attenuation of pain behaviours, levels of COX-2 returned to control levels. Significant
induction of Egr-1 mRNA and protein were observed in spinal cord from lame animals. Three days after treatment,
levels of Egr-1 mRNA returned to control levels, however, Egr-1 protein remained elevated.
Conclusion: Elevated levels of spinal COX-2 and Egr-1 protein correlate with the presence of pain and
hyperalgesia, and may underlie persistent pain, although a direct causal link has still to be established.
Understanding the temporal pattern of expression of key mediators in clinical pain states may lead to better
strategies to manage pain.
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Background
While experimental models of inflammatory pain have
helped increase our understanding of pain mechanisms,
they are sometimes limited in addressing the diverse
nature of clinical pain, focussing more on short-term
cellular and molecular changes. Furthermore, they do
not represent the heterogeneity of clinical pain states.
The present study utilized a model of naturally-occur-
ring persistent inflammation, pain and hyperalgesia in
sheep, induced by a bacterial infection of the digital tis-
sues of the feet of ruminants, known as ‘footrot’ [1,2].
‘Footrot’ is a painful, chronic disease of sheep, where
the anaerobic bacterium Dichelobacter nodosus is the
primary pathogen [3]. ‘Footrot’ induces inflammation of
the digital skin and underlying tissues, and typically
extends abaxially to cause separation and under-run
lesions of the keratin matrix of the hoof. Footrot is con-
sidered an economically significant disease, and to have
an adverse effect on animal welfare. Both body weight
and wool production are adversely affected during the
clinical phase of the infection [4]. Hyperalgesia has been
documented in sheep with footrot [2,5] and studies have
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identified alterations in a number of pain-related genes
in spinal cord recovered from these animals [2].
Prostaglandins (PGs), released by the action of
cyclooxygenases (COX-1 and COX-2) on arachidonic
acid, contribute to spinal nociception and hyperalgesia
[6-9]. COX-2 is the major source of PGs in inflamma-
tory pain, and the target for COX-2 selective non-steroi-
dal anti-inflammatory drugs (commonly known as
coxibs). COX-2 is induced in spinal cord in response to
a variety of inflammatory stimuli [7,10-15], and is asso-
ciated with the central component of hyperalgesia [16],
and as such, may prove to be a useful marker of spinal
cord plasticity underlying persistent hyperalgesia.
The transcription factor, early growth response gene 1
(Egr-1) also known as zif268, Krox-24 and NGFI-A, is
also regulated by neuronal activity, and is generally con-
sidered a model system to study synaptic plasticity
[17,18]. Egr-1 expression increases during long-term
potentiation (LTP) [19,20], and is required for encoding
long-lasting memories (see review by Davis et al. [18]).
Egr-1 is rapidly induced in spinal cord in response to
sensory fibre stimulation [20-22] and following periph-
eral inflammation [23-27], suggesting a role for Egr-1
regulated target gene expression and persistent cell
modifications in spinal cord neuronal plasticity and per-
sistence of pain. Evidence that Egr-1 induction is depen-
dent on NMDA receptor activation [27,28], and
increased intracellular Ca2+ concentration (see review by
Thiel et al. [29]), both triggers of activity-dependent
central sensitization [30] support this hypothesis.
This study was designed to characterise the effects of
long-lasting clinical inflammation on pain behaviours
and spinal cord nociceptive information processing
while monitoring established markers of central neuro-
nal plasticity, COX-2 and Egr-1, to determine the effec-
tiveness of treatment on resolution of these behaviours.
Results show that COX-2 and Egr-1 mRNA and protein
expression in spinal cord correlate with the presence of
pain and hyperalgesia, suggesting that these mediators,
and their downstream targets, contribute to pain related
plasticity in spinal cord pathways.
Results
Resolution of hyperalgesia after treatment
In healthy control animals, there was no significant dif-
ference in mechanical withdrawal threshold recorded
from all four legs for the duration of the study (Figure
1b). Prior to treatment, sheep affected by unilateral
lameness had reduced response thresholds to mechani-
cal stimulation in the lame limb compared to non-
affected limbs and control animal limb thresholds (Fig-
ure 1b). Sheep affected by unilateral lameness displayed
significant hyperalgesia (p < 0.001 vs. control sheep) on
day 0 prior to treatment, which was attenuated 1 day
following treatment (p < 0.001 vs. day 0), and fully
resolved by day 7 after treatment (p < 0.01 vs. day 0),
when thresholds were similar to those observed in con-
trol animals. Data collected from each lame sheep are
presented in Table 1.
Lameness Scores
On day 0 prior to treatment, mean lameness scores were
6.6 ± 0.3 in sheep affected by unilateral lameness (Table
1). There was a significant (p < 0.001 vs. day 0) decrease
in lameness scores just 1 day following treatment, fol-
lowed by a further significant (p < 0.001 vs. day 0)
decrease in lameness 3 days post-treatment. No further
resolution in lameness was observed, and some animals
remained mildly lame at day 7 (1.8 ± 0.5; Figure 1c).
Foot Pathology
On day 0 prior to treatment, the median pathology
score was 4 (range 2-4); by day 3 the median score had
dropped significantly (p < 0.01) to 2.5 (range 0-4),
although, in 5 out of the 18 sheep examined there was
no noticeable improvement in foot condition. No
further improvement in foot pathology was observed by
7 days (median score 2 (range 0 - 4)).
Lymph Node Pathology
In control animals, left and right lymph nodes were of
approximately equal size (2.0 ± 0.2 g and 1.9 ± 0.2 g,
respectively; Figure 2b). In contrast, the ipsilateral
lymph nodes obtained from lame animals prior to treat-
ment (7.2 ± 0.8 g) were significantly enlarged (p <
0.001) compared to the contralateral nodes (2.9 ± 0.4 g)
and compared to control sheep lymph nodes. Lymph
nodes collected from animals on day 3 after treatment
were still significantly enlarged (13.5 ± 2.1 g) compared
to contralateral nodes (2.4 ± 0.2 g) and compared to
control sheep lymph nodes.
Expression of COX-1, COX-2 and Egr-1 in spinal cord
COX-1, COX-2 and Egr-1 mRNA were constitutively
expressed in spinal cord collected from control sheep (Fig-
ure 3). No change was detected in expression of COX-1 or
COX-2 mRNA in ipsilateral or contralateral spinal cord in
lame animals on day 0 or day 3 post-treatment compared
to control animals. Significant up-regulation of Egr-1
mRNA was detected in ipsilateral spinal cord in lame ani-
mals on day 0 before treatment compared to control ani-
mals (4.5 fold decrease; p < 0.05). Levels had returned to
control levels by day 3 after treatment.
Expression of COX-1, COX-2 and Egr-1 protein in spinal
cord
Western blot analyses of protein extracts prepared from
spinal cord homogenates revealed COX-1 and COX-2
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antibody labelled bands at approximately 70 and 72 kDa,
respectively, as expected (Figure 4). The antibody to Egr-
1 detected bands at approximately 60 kDa, as expected
(Figure 4). A significant up-regulation in COX-2 protein
expression was found in ipsilateral and contralateral
spinal cord from lame animals on day 0 relative to con-
trol animals (both p < 0.05 relative to control animals
(100%)). COX-2 expression returned to control levels 3
days after treatment. No change was detected in levels
of COX-1 protein in spinal cord between groups. Egr-1
Figure 1 Resolution of lameness and hyperalgesia after treatment. Photograph of a clinically lame animal and close-up of the hindfeet (a).
The animal was given a lameness score of 10 (non-weight bearing). Inflammation can be seen in the right foot and tracking up the lower limb.
The magnitude of hyperalgesia (Emax%) on the lame limb on day 0 prior to treatment, and up to 7 days post-treatment is represented as the
percentage change from 3 non-affected limbs according to the formula: ((mean response threshold of non-affected limbs - response threshold of
lame limb)/mean response threshold of non-affected limbs) × 100. In control animals, the mean percentage change in response threshold
measured on one limb relative to the three other limbs was calculated (b). Mean lameness score for animals affected by unilateral lameness on
day 0 prior to treatment for lameness, and up to 7 days post-treatment (c). Data are presented as mean values; s.e.d. represents the standard
error of the difference. a, b, c Means with disparate letters are significantly different (p < 0.05).
Dolan et al. Molecular Pain 2011, 7:91
http://www.molecularpain.com/content/7/1/91
Page 3 of 10
protein levels were significantly increased in ipsilateral
spinal cord from lame animals on day 0 (p < 0.05 rela-
tive to control animals (100%)), and this up-regulation
persisted 3 days after treatment (p < 0.05 relative to
control animals (100%)). Further analyses, however,
revealed that levels Egr-1 proteins were decreased in
ipsilateral spinal cord 3 days after treatment relative to
levels in lame sheep on day 0 (p < 0.05; Figure 4).
Discussion
This study describes a unique approach to the neuro-
biology of the resolution of clinical inflammatory pain.
The model of inflammatory pain used in this study, has
been described previously and is an excellent model of
naturally-occurring pain [1,2]. Strict inclusion criteria
were adhered to and from clinical examination animals
recruited to the study were estimated to have had the
infection for more than two weeks. Therefore, this
model is representative of persistent pain. The condition
‘footrot’ is initiated by invasion of bacteria into the
interdigital tissues inducing dermatitis, and as infection
spreads the bacteria penetrate further into deep tissues
causing extensive tissue damage and separation of the
hoof horn, accompanied by inflammation and pain [31].
To contain the clinical heterogeneity of diseased ani-
mals, only sheep with lameness scores ≥ 5 and pathol-
ogy scores ≥ 2, were recruited. As expected, animals
affected with unilateral inflammation displayed signifi-
cant lameness (taken as a proxy indicator of sponta-
neous pain) and hyperalgesia, restricted to the inflamed
limb. Previous studies in this laboratory revealed a sig-
nificant relationship between lameness score and
mechanical hyperalgesia, supporting a positive associa-
tion between the magnitude of hyperalgesia and the
intensity of inflammatory pain [2]. The presence of
mechanical hyperalgesia localised to the inflamed limb
Table 1 Lameness, pathology and hyperalgesia score assessed in sheep before and after treatment.
Sheep i.d. Lame Leg DAY 0 DAY 3
Lameness Score Pathology Score Emax (%) Lameness Score Pathology Score Emax (%)
Y45 LH 8 4 62.6 2 4 19.2
W140 RH 8 4 47.7 1 4 25.5
G122 LF 7 4 59 3 2 -7.2
R5 RF 7 4 71.4 2 1 19.8
Y36 RH 8 3 29.3 1 1 3.7
G97 LF 6 4 62.9 4 4 62.9
B93 RF 8 2 40.7 1 0 27.9
Y56 RF 6 4 38.5 3 2 41.4
W15 LF 5 3 33.4 4 3 -13.0
237 LH 7 2 29.9 2 0 5.1
G117 RF 6 2 16.7 0 0 8.75
394 LH 4 4 25.5 5 3 3.3
B83a RH 8 4 58.4 - - -
G60a LH 6 4 32.7 - - -
G146a RH 7 3 63.9 - - -
B23a RH 5 2 52.7 - - -
W110a LH 5 2 42.5 - - -
B801a RH 5 2 55.2 - - -
B1b RH 6 3 47.4 3 3 -8.27
RSb RH 5 4 49.5 5 3 48.9
Y192b LH 5 4 52.0 4 3 31.7
B24b RH 4 4 41.0 4 3 -17.5
B69b LH 4 2 31.6 1 1 2.6
B93b LH 4 4 37.6 2 1 2.6
MEAN (± sem) 6.6 ± 0.3 45.1 ± 2.9 2.6 ± 0.3 15.0 ± 4.6
MEDIAN (range) 4 (2-4) 2.5 (0-4)
Mean lameness (± SEM) and median pathology (range) scores and mean magnitude of hyperalgesia (Emax), represented as the percentage change in response
threshold from the non-lame limbs, for 24 sheep affected by unilateral lameness recorded on day 0 before treatment, then on day 3 after treatment. LH-left
hindleg; RH-right hindleg; LF-left foreleg; RF-right foreleg; a - sheep euthanased on day 0 before treatment; b - sheep euthanased 3 days after treatment.
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indicates an alteration in sensory nerve function and
nociceptive processing occurring centrally, as a conse-
quence of release of pro-inflammatory mediators at the
site of inflammation and at spinal cord level. Previous
studies have shown that parenteral and topical antibac-
terial treatment produces rapid recovery (within 5 days
of treatment) from foot lesions and lameness in sheep
with footrot [32]. In the present study, antiseptic
footbathing, trimming the hoof horn and parental anti-
biotics rapidly reversed both lameness and hyperalgesia,
with more than 85% of animals showing significant
improvements 3 days after treatment, despite the persis-
tence of foot pathology and lymph node hyperplasia.
These findings indicate that treating the primary source
of infection and therefore reducing inflammation is
effective and sufficient to reverse persistent pain hyper-
sensitivity in this clinical model.
The bilateral induction of COX-2 protein in spinal
cord from sheep with inflammation and subsequent
decrease in expression 3 days after treatment as lame-
ness and hyperalgesia were resolving, supports the
theory derived from experimental models that that
spinal COX-2 derived PGs play a key role in central
mechanisms of hyperalgesia in clinical pain [33-36]. A
bilateral and inter-segmental induction of spinal COX-2
in response to unilateral inflammation induced by injec-
tion of complete Freund’s adjuvant (CFA) into the foot-
pad in rat has been described previously [12,15],
suggested to be due to a humoral response induced by
circulating pro-inflammatory mediators such as IL-1b. A
humoral immune response could account for the bilat-
eral increase in COX-2 protein in spinal cord observed
in the present study, however, no corresponding
increase in levels of COX-2 were detected in spinal cord
segments distal to the inflamed limb afferent termina-
tion site (data not presented). It is likely that increased
noxious input from activated primary afferents from the
inflamed limb, driving activity of spinal dorsal horn neu-
rons, contribute to induction of COX-2, perhaps
through activation of substance P, which is known to
lead to increased expression of COX-2 and release of
PGE2 in spinal cord [37]. Induction of COX-2 in spinal
Figure 2 Lymph node hyperplasia in infected sheep. Photograph of popliteal lymph nodes ipsilateral and contralateral to inflamed limb
collected from a clinically lame animal (a). Mean lymph node size (each lymph node represented as proportion (%) of combined weight) in
control animals (left and right prescapular and popliteal lymph nodes) and animals affected by unilateral hindlimb (popliteal lymph nodes) and
forelimb (prescapular lymph nodes) lameness on day 0 prior to treatment, and 3 days post-treatment (b). Data are presented as mean values; s.e.
d. represents the standard error of the difference. a, b, c Means with disparate letters are significantly different (p < 0.001).
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cord appears to be transient in most rodent models of
inflammation, for instance, peaking 6 hours after hind-
paw incision or intraplantar injection of carrageenan
[38], and between 6-12 hours in response to injection of
CFA into the footpad; returning to baseline levels a few
days later [11,12,15], even though hyperalgesia and paw
inflammation persists for several days beyond this per-
iod in this model [12,39,40]. These studies indicate that
COX-2 in spinal cord plays key role in initiating central
sensitization with acute inflammation. The elevated
levels of COX-2 protein observed in spinal cord from
sheep with persistent inflammatory disease, however,
suggests that COX-2 derived PGs also contribute to
maintaining the central component of hyperalgesia in
this model. This is supported by a recent study by Pro-
chazkova et al. [41] showing long-lasting up-regulation
of COX-2 mRNA and protein in spinal cord in a model
of osteoarthritis and persistent hyperalgesia.
Biosynthesis of Egr-1 mRNA and protein was
increased in ipsilateral spinal cord from sheep with
unilateral inflammation, also likely due to increased
input from activated nociceptors in the inflamed limb.
Egr-1 is primarily expressed in superficial dorsal horn
neurons that receive input from small-diameter myeli-
nated and unmyelinated afferent fibres [22,25], and
expression is rapidly induced in these laminae in
response to a variety of acute experimental inflamma-
tory stimuli including intraplantar injection of formalin
[24,26,27] and carrageenan [25], and nerve-injury [42].
Furthermore, the temporal pattern of Egr-1 expression
is reported to parallel development of hyperalgesia and
inflammation [23,25], suggesting a link between Egr-1
expression and behavioural responses to inflammatory
pain. This hypothesis was further strengthened by a
study in Egr-1 knockout mice by Ko et al. [43], that
reported that although acute nociception is unaltered,
hypersensitivity induced by formalin or CFA was
diminished in these mice. A role for spinal Egr-1 in
the maintenance of inflammatory pain is supported by
evidence that Egr-1 antisense treatment in rat resulted
in deficits in the maintenance of mechanical allodynia
[21]. In the present study, the return of Egr-1 mRNA
levels to baseline levels and decrease in protein expres-
sion 3 days after treatment, as lameness and hyperalge-
sia were resolving, further strengthens a role for Egr-1
in central neuronal plasticity underlying inflammatory
or persistent pain.
Egr-1 activates a variety of downstream target genes
by binding to the DNA sequence GCG(G/T)GGCG in
the genes promoter region, including microsomal pros-
taglandin E synthase-1 (mPGES-1), the enzyme that
couples with COX-2 to produce PGE2 [44], and COX-
2 [45], suggesting an interaction between Egr-1 regu-
lated transcription and inflammatory prostanoid pro-
duction. This hypothesis is supported by evidence that
inhibition of Egr-1 results in decreased COX-2 and
mPGES-1 expression in LPS-stimulated murine macro-
phages [45], and induction of mPGES-1 mRNA follow-
ing injurious ventilation in lung tissues is diminished
in Egr-1 knockout mice [46]. Inflammatory prostaglan-
dins also seem to play an important regulatory
upstream role, acting as initiators of Egr-1 activity. For
instance, treatment of stimulated endothelial cells with
Figure 3 Expression of COX-1, COX-2 and Egr-1 mRNA in spinal
cord. Real-time semi-quantitative measurement of COX-1 (a), COX-2
(b) and Egr-1 (c) mRNA in spinal cord from control sheep (n = 6)
and sheep affected by unilateral lameness on day 0 (pre-treatment)
(n = 6) and 3 days post-treatment (n = 6). Spinal cords were
hemisected into ipsilateral and contralateral portions (data is pooled
for control animals). Levels of mRNA are expressed relative to the
endogenous reference gene b-actin. Significant increase from
control: * p < 0.05.
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a COX-2 selective inhibitor was reported to inhibit
production of Egr-1 mRNA and protein [47], while
PGE2 induces Egr-1 mRNA expression cementoblastic
OCCM periodontal cells [48]. The co-induction of
COX-2 and Egr-1 in spinal cord from sheep with uni-
lateral inflammation and hyperalgesia supports a link
between the COX-2 signalling pathway and enhanced
Egr-1 gene transcription, and may underlie persistent
cell modifications at the spinal level and persistence of
pain.
Conclusion
These data provide valuable information on the tem-
poral pattern of expression of plasticity-related genes in
spinal cord with resolution of naturally-occurring persis-
tent inflammatory disease and associated pain. It is
hypothesised that the biosynthesis of COX-2 and Egr-1
contribute to pain related synaptic potentiation in spinal
cord pathways by mediating long lasting changes in
expression of downstream targets and persistent altera-
tions in neuronal functioning. The rapid decrease in
COX-2 and Egr-1 expression with diminished pain and
hyperalgesia following treatment of peripheral inflamma-
tion, suggest that these mediators and their downstream
targets may be targeted to prevent the evolution of per-
sistent pain into chronic pain.
Methods
The study was approved by the Institute’s Ethics and
Welfare committee and all procedures were performed
according to the UK Animal Scientific Procedures Act
(1986). Animals were treated in accordance with the
Ethical Guidelines for Investigations of Experimental
Pain in Conscious Animals as issued by the Interna-
tional Association for the Sudy of Pain.
Clinical model of persistent inflammation and
hyperalgesia
A total of 45 adult ‘Scottish Mule’ ewes were used in
this study, consisting of 24 sheep affected by unilateral
inflammation-induced lameness ("footrot"- Figure 1),
and 21 age-matched healthy control sheep selected from
the same flock for euthanasia due to poor dentition or
poor fertility. All lame sheep were examined clinically
by an experienced observer on day 0 (prior to treat-
ment) and a diagnosis made as appropriate. Only ani-
mals affected by unilateral ‘footrot’ fitting the selection
criteria (described below) were recruited into the study.
Control animals were also examined to exclude the pre-
sence of any other clinical signs of disease.
All unilaterally lame sheep were scored for lameness
severity using an 11-point numerical rating scale (0-10;
where 0 = normal and 10 = could not be more lame, i.e.
Figure 4 Expression of COX-1, COX-2 and Egr-1 proteins in spinal cord. Western blot analyses of COX-1 (a), COX-2 (b) and Egr-1 (c) protein
in spinal cord. Photomicrographs show expression of COX-1, COX-2 and Egr-1 at 70, 72 and 60 kDa, respectively, as expected in a representative
control sample (con) and ipsilateral (i) and contralateral (c) spinal cord from an animal affected by unilateral lameness on day 0. Graphs show
densitometric quantification of levels of COX-1 (a), COX-2 (b) and Egr-1 (c) protein in ipsilateral and contralateral spinal cord tissues from animals
affected by unilateral lameness on day 0 before treatment (n = 6) and 3 days after treatment (n = 6). Bars represent mean ± SEM protein
expression (as %) relative to control levels (100%). Significant increase from control: * p < 0.05; significant decrease from day 0: * p < 0.05.
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not weight bearing), as previously described [49]. In
addition, the affected digit was scored for pathology
using a simple 5-point descriptive scale (0-4; Table 2) as
described by Ley et al. [1]. Only sheep with lameness
and pathology scores of ≥ 5 and ≥ 2, respectively, were
recruited onto the study. All ‘footrot’-affected sheep
recruited had pathological lesions indicative of duration
in excess of 2 weeks.
Following initial behavioural testing on day 0, selected
animals were treated according to standard farm prac-
tice; foot paring (trimming off diseased horn), foot-bath-
ing for 10 min in 10% zinc sulphate (Golden Hoof Plus;
Sheep Fair Products Ltd., UK), and antibiotic (oxytetra-
cycline) therapy administered parenterally (Duphacy-
cline™ LA (Fort Dodge Animal Health Ltd., UK); 20 mg
kg-1 bodyweight, i.m.).
Lymph node pathology
Left and right pre-scapular and popliteal lymph nodes
were obtained following euthanasia from sheep with
hindlimb lameness on day 0 (n = 6) before treatment,
and on day 3 after treatment (n = 6), and weighed for
size analysis to further confirm unilateral inflammation.
In control sheep (n = 6), left and right pre-scapular and
popliteal lymph nodes were collected for size compari-
son with those obtained from lame animals.
Behavioural testing
Withdrawal thresholds to noxious mechanical stimula-
tion were measured according to a method used pre-
viously by our group [50]. In lame sheep, thresholds
were measured on day 0 (n = 24), and 1 (n = 18), 2 (n =
18), 3 (n = 18) and 7 (n = 12) days post-treatment. In
control animals, thresholds were also measured on day
0 (n = 21), and 1, 2, 3 and 7 (n = 10) days post-treat-
ment. In brief, a pneumatic device connected to a cali-
brated pressure meter (C9595 IS, Comark, UK) was
used to push a blunt pin, positioned on the skin of the
leg, with increasing force until a withdrawal response
was evoked. The minimum force required to evoke a
clear lifting of the limb from the ground was defined as
the withdrawal response threshold. This procedure was
repeated 2-4 times at each time point. Readings from
the pressure meter (mBar) were subsequently converted
into force (Newtons; N). A cut-off threshold of 30 N
was employed.
Real-time PCR
Real-time PCR was performed on spinal cord tissue (L6-
S2) from control animals (n = 6) and animals affected
by unilateral hindlimb lameness. Tissue was utilised
from lame animals euthanased (Somulose™ (Arnolds,
UK); 1 ml 10 kg-1 bodyweight, i.v.) on day 0 (n = 6) and
on day 3 (n = 6) post-treatment. Spinal cord samples
were hemisected into ipsilateral (side of pathological
lesion) and contralateral sections. Total RNA was then
extracted from spinal cord using TRIZOL® Reagent
(Invitrogen, UK), and reverse transcribed using random
hexamers (Promega, UK) and M-MLV reverse transcrip-
tase (Invitrogen, UK). Semi-quantitative real-time PCR
was performed on cDNA for ovine COX-1, COX-2 and
Egr-1 and the endogenous reference gene b-actin
(MWG-Biotech AG, Germany), using a MX3000P® Q-
PCR system (Stratagene, UK). The PCR reaction was
performed using Thermo-Start® DNA polymerase
(ABgene, UK) as described in Dolan et al. [2]. Samples
were run in duplicate for each quantification assay. For
relative quantification of target gene mRNA the com-
parative Ct (cycle threshold) method was used as
described in Dolan et al. [2], which involves normalisa-
tion of the number of target gene copies to the refer-
ence genes.
Western blotting
Western blots were performed on spinal cord (L6-S2)
tissue protein extracts from control animals (n = 6) and
animals affected by unilateral hindlimb lameness. Tissue
was utilised from lame animals euthanased on day 0 (n
= 6) prior to treatment and on day 3 (n = 6) post-treat-
ment. Spinal cord samples were hemisected into ipsilat-
eral and contralateral sections. Protein was isolated
using RIPA buffer, which enables extraction of cytoplas-
mic, membrane and nuclear proteins, as previously
described by our group [2]. Prior to loading, protein
supernatants were diluted in loading buffer (NuPage®
LDS sample buffer, 1 × final concentration (Invitrogen,
UK); 0.05 M DTT) to a final concentration of 2 mg ml-1
and incubated for 10 min at 90°C. Diluted protein
lysates (30 μg spinal cord) and protein molecular weight
markers (SeaBlue Plus 2® Pre-Stained Standard and
Magic Mark™ XP (Invitrogen, UK)) were loaded onto
NuPage® Novex 4-12% Bis-Tris gels (Invitrogen, UK),
and run for 50 min at 200 V. Proteins were transferred
onto PVDF membranes (Invitrogen, UK) at 30 V for 1 h
using a semi-dry blotting system. Membranes were
blocked in 0.1 M PBS; 5% skimmed milk proteins; 5%
BSA; 0.1% Tween® 20 for 1 h at room temperature.
Table 2 Pathology scoring system adopted to assess
lesion severity in lame sheep.
Score Criteria
0 Normal foot
1 Damage to hoof; inflamed digital tissues; no smell
2 Foot swollen and hot; inflamed digital tissues
3 Foot swollen and hot; inflamed digital tissues; broken hoof
4 Foot swollen and hot; inflamed digital tissues; broken hoof; foul
odour
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Following blocking, membranes were incubated over-
night at 4°C with COX-1 (ovine polyclonal; 1:1000; Cay-
man Chemical, USA) or COX-2 (murine polyclonal;
1:1000; Cayman Chemical, USA) or Egr-1 primary anti-
sera (rabbit polyclonal; 1:1000; Santa Cruz Biotechnol-
ogy, Inc. USA) diluted in blocking buffer. Immunoblots
were then washed for 3 × 5 min in 0.1 M PBS; 0.1%
Tween® 20 prior to incubation for 1 h at room tem-
perature in secondary antibody (donkey anti-rabbit IgG,
HRP-linked whole antibody; 1:1,000; Amersham Bios-
ciences, UK) solution diluted in blocking buffer. Immu-
noblots were then washed for 3 × 5 min in 0.1 M PBS;
0.1% Tween®20. Following washing, immunoblots were
developed and visualised by enhanced chemilumines-
cence ECL™ detection reagents and Hyperfilm™
(Amersham Biosciences, UK). Immunoreactivity was
quantified using a calibrated imaging densitometer (GS-
710™, Bio-Rad UK) linked to PC-based analysis soft-
ware (Quantity One®, Bio-Rad UK).
Statistical analyses
The magnitude of hyperalgesia (Emax) on the lame limb
is represented as the percentage change from each ani-
mal’s three other non-affected limbs according to the
formula: ((mean response threshold of non-affected
limbs - response threshold of lame limb)/mean response
threshold of non-affected limbs) × 100. In control ani-
mals, the mean percentage change in response threshold
measured on one limb relative to the three other limbs
was calculated. The effect of time after treatment on the
magnitude of hyperalgesia or lameness was analysed as
a repeated measurements design using a residual maxi-
mum likelihood (REML) program. REML analysis was
carried out due to non-orthogonality as a result of the
imbalance in animal numbers between groups and time.
Significant differences in the magnitude of hyperalgesia
or lameness were tested using least significant differ-
ences, determined using the standard error of the differ-
ence (s.e.d.) obtained from the REML analyses.
Lymph node size is represented as the percentage of
the total weight that each ipsilateral and contralateral
lymph node contributes according to the formula: (ipsi-
lateral lymph node weight/(ipsilateral + contralateral
lymph node weight)) × 100. Data from forelimb and
hindlimb lame animals were pooled and analysed
together as initial analysis indicated no difference in
response between pre-scapular and popliteal lymph
nodes. Lymph node data were analysed using analysis of
variance, and post-hoc least significant difference tests
provided tests for differences between treatment groups,
and ipsilateral and contralateral lymph node.
Real-time PCR data were analysed using an out using
analysis of variance adopting a general linear model rou-
tine with post-hoc Tukey’s test (Mintab, v. 14). Western
blot data were converted to percentages of control
values and statistical significance assessed using analysis
of variance (Minitab, v13.1). The 95% confidence inter-
vals were used for comparisons between treatment
groups and controls (100%).
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